ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.
Okada M, Yamasaki S, Nakazato H, Hirahara Y, Ishibashi T, Kawamura M, Shimizu K, Fujii SI.

ARID1A restrains EMT and stemness of ovarian cancer cells through the Hippo pathway.
Xu S, Zhu C, Xu Q, An Z, Xu S, Xuan G, Lin C, Tang C., Free PMC Article

ARID1A in Gynecologic Precancers and Cancers.
Morgan JE, Jaferi N, Shonibare Z, Huang GS.

ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.
Maxwell MB, Hom-Tedla MS, Yi J, Li S, Rivera SA, Yu J, Burns MJ, McRae HM, Stevenson BT, Coakley KE, Ho J, Gastelum KB, Bell JC, Jones AC, Eskander RN, Dykhuizen EC, Shadel GS, Kaech SM, Hargreaves DC.,

Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
Li S, Meersma GJ, Kupryjanczyk J, de Jong S, Wisman GBA., Free PMC Article

Prognostic role of transcription factor ARID1A in patients with endometrial cancer of no specific molecular profile (NSMP) subtype.
Onoprienko A, Hofstetter G, Muellauer L, Dorittke T, Polterauer S, Grimm C, Bartl T.

ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response.
Bakr A, Della Corte G, Veselinov O, Kelekçi S, Chen MM, Lin YY, Sigismondo G, Iacovone M, Cross A, Syed R, Jeong Y, Sollier E, Liu CS, Lutsik P, Krijgsveld J, Weichenhan D, Plass C, Popanda O, Schmezer P., Free PMC Article

Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: A multicenter real-world study.
Ottaiano A, Santorsola M, Diana A, Belli A, Lentini Graziano ML, Orefice J, Patrone R, Di Mauro A, Scognamiglio G, Tatangelo F, De Bellis M, Piccirillo M, Fiore F, Stilo S, Tarotto L, Correra M, Di Lorenzo S, Capuozzo M, Avallone A, Silvestro L, Bianco A, Granata V, Federico P, Montesarchio V, Daniele B, Izzo F, Nasti G., Free PMC Article

Deep-targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma.
Xiao M, Cui X, Xu C, Xin L, Zhao J, Yang S, Hong B, Tan Y, Zhang J, Li X, Li J, Kang C, Fang C., Free PMC Article

ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.
Barisic D, Chin CR, Meydan C, Teater M, Tsialta I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE, Raggiri S, Debek S, Pelzer B, Durmaz C, Deng Q, Lakra P, Rivas M, Steidl C, Scott DW, Weng AP, Mason CE, Green MR, Melnick A.,

Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations.
D'Ambrosio A, Bressan D, Ferracci E, Carbone F, Mulè P, Rossi F, Barbieri C, Sorrenti E, Fiaccadori G, Detone T, Vezzoli E, Bianchi S, Sartori C, Corso S, Fukuda A, Bertalot G, Falqui A, Barbareschi M, Romanel A, Pasini D, Chiacchiera F., Free PMC Article

The ARID1A-METTL3-m6A axis ensures effective RNase H1-mediated resolution of R-loops and genome stability.
Zhang J, Chen F, Tang M, Xu W, Tian Y, Liu Z, Shu Y, Yang H, Zhu Q, Lu X, Peng B, Liu X, Xu X, Gullerova M, Zhu WG.

ARID1A loss is associated with increased NRF2 signaling in human head and neck squamous cell carcinomas.
Nguyen V, Schrank TP, Major MB, Weissman BE., Free PMC Article

ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance.
Huang R, Wu D, Zhang K, Hu G, Liu Y, Jiang Y, Wang C, Zheng Y., Free PMC Article

The Role of the AT-Rich Interaction Domain 1A Gene (ARID1A) in Human Carcinogenesis.
Li JJ, Lee CS., Free PMC Article

ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma.
Xing T, Li L, Rao X, Zhao J, Chen Y, Ju G, Xu Y, Gao X, Dong G, Xia X, Guan Y, Zhang L, Wen Z, Liang J., Free PMC Article

ARID1A loss activates MAPK signaling via DUSP4 downregulation.
Mandal J, Yu ZC, Shih IM, Wang TL., Free PMC Article

Coexistent ARID1A-PIK3CA mutations are associated with immune-related pathways in luminal breast cancer.
Anabel Sinberger L, Zahavi T, Sonnenblick A, Salmon-Divon M., Free PMC Article

Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells.
Xing B, Zhang X, Gu X, Xiang L, Wang C, Jin Y.

Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma.
Xing T, Li L, Chen Y, Ju G, Li G, Zhu X, Ren Y, Zhao J, Cheng Z, Li Y, Xu D, Liang J., Free PMC Article

Clinicopathologic Features and the Loss of ARID1A Expression in Ovarian Seromucinous Borderline Tumors and Seromucinous Carcinomas.
Ok Atılgan A, Özen Ö, Haberal Reyhan AN, Ayhan A.

Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
Chen XY, Li B, Wang Y, Jin J, Yang Y, Huang LH, Yang MD, Zhang J, Wang BY, Shao ZM, Ni T, Huang SL, Hu XC, Tao ZH., Free PMC Article

ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.
Jin F, Yang Z, Shao J, Tao J, Reißfelder C, Loges S, Zhu L, Schölch S.

CDK12 alterations and ARID1A mutations are predictors of poor prognosis and therapeutic targets in high-grade salivary gland carcinoma: analysis of the National Genomic Profiling Database.
Kobayashi K, Saito Y, Kage H, Fukuoka O, Yamamura K, Mukai T, Oda K, Yamasoba T.

Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.
Xu C, Huang KK, Law JH, Chua JS, Sheng T, Flores NM, Pizzi MP, Okabe A, Tan ALK, Zhu F, Kumar V, Lu X, Benitez AM, Lian BSX, Ma H, Ho SWT, Ramnarayanan K, Anene-Nzelu CG, Razavi-Mohseni M, Abdul Ghani SAB, Tay ST, Ong X, Lee MH, Guo YA, Ashktorab H, Smoot D, Li S, Skanderup AJ, Beer MA, Foo RSY, Wong JSH, Sanghvi K, Yong WP, Sundar R, Kaneda A, Prabhakar S, Mazur PK, Ajani JA, Yeoh KG, So JB, Tan P, Singapore Gastric Cancer Consortium.